Ozempic reduces severity of liver disease in people with HIV, study
shows
Send a link to a friend
[March 06, 2024]
(Reuters) -A weekly injection of semaglutide was safe and reduced
the amount of fat in the liver by 31% in people with HIV and a type of
liver disease, data from a mid-stage study funded by the National
Institutes of Health showed.
Data from the study was first released on Monday at the Conference on
Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado.
This is the first trial showing the effects of semaglutide in HIV
patients with a type of liver disease known as Metabolic
dysfunction-associated steatotic liver disease (MASLD).
Semaglutide is the active ingredient in Novo Nordisk's popular weight
loss drug Wegovy and diabetes treatment Ozempic.
MASLD, previously known as nonalcoholic fatty liver disease, is
characterized by the accumulation of excess fat in the liver that is not
caused by alcohol consumption or viral hepatitis.
![](http://archives.lincolndailynews.com/2024/Mar/06/images/ads/current/ldn_booksda_CHASSKAREN_010924.png)
The study enrolled adult patients with the disease whose viral load -
the amount of HIV in the blood - was suppressed to undetectable levels
by antiretroviral therapy (ART).
Patients saw an average 31% reduction in liver fat, with 29% of
participants experiencing a complete resolution of MASLD, resulting in
their liver fat decreasing to 5% or less of overall liver content.
Of the 49 patients included in the data analysis, 40 were taking ART
regimens containing a class of drugs known as integrase strand transfer
inhibitors.
[to top of second column]
|
![](../images/030624PIX/health2.jpg)
Scientific model of the molecule semaglutide which is the active
ingredient in Novo Nordisk's mega-blockbuster diabetes drug Ozempic
and weight-loss drug Wegovy sits in the office of Mads Krogsgaard
Thomsen in Hellerup, Denmark, October 3, 2023. REUTERS/Ali
Withers/File Photo
![](http://archives.lincolndailynews.com/2024/Mar/06/images/ads/current/graue_lda_preowned_030424.jpg) Integrase strand transfer inhibitors
have shown to be effective for suppressing HIV, but are also
associated with weight gain in some patients.
Eli Lilly's tirzepatide, the active ingredient in its popular
diabetes drug Mounjaro, helped up to 74% of patients achieve absence
of a severe type of fatty liver disease with no worsening of liver
scarring at 52 weeks in a mid-stage trial.
Lilly's trial is testing its drug in patients without HIV.
Novo is testing semaglutide in a separate late-stage trial in
patients with the same condition.
(Reporting by Sriparna Roy in Bengaluru; Editing by Krishna Chandra
Eluri)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
![](http://archives.lincolndailynews.com/2024/Mar/06/images/ads/current/humanesociety_sda022411.png) |